RXDX-101 is an investigational drug that inhibits altered versions of the proteins TRKA, TRKB, TRKC, ROS1, or ALK. When these proteins are altered, they can cause normal cells to become abnormal and form tumors. Laboratory studies have shown that RXDX-101 can shrink tumors with molecular changes in these proteins.
The purpose of this study is to find the highest dose of RXDX-101 that can be given safely in patients with locally advanced or metastatic cancers containing alterations in the TRKA, TRKB, TRKC, ROS1, or ALK proteins. RXDX-101 is taken orally (by mouth).